TRAIL及其受体TRAIL-R2与TRAIL-R4在人非小细胞肺癌中表达及其临床意义

发布时间：2018-01-09 06:30

本文关键词：TRAIL及其受体TRAIL-R2与TRAIL-R4在人非小细胞肺癌中表达及其临床意义　出处：《山西医科大学》2015年硕士论文　论文类型：学位论文

更多相关文章： 非小细胞肺癌 TRAIL TRAIL-R2 TRAIL-R4

【摘要】：目的:研究肿瘤坏死因子相关凋亡诱导配体(tumor necerosis factor-related apoptosis-inducing ligand,TRAIL)及其受体TRAIL-R2(DR5)与TRAIL-R4(Dc R2)在非小细胞肺癌(non-small lung cancer,NSCLC)中的表达规律,分析其与非小细胞肺癌(NSCLC,Non-small Cell Lung Cancer)的病理分型、分化水平、临床分期的关系,为临床上早发现,早治疗提供实验室依据,并且初步探讨了TRAIL用于临床的研究。方法:采用酶联免疫吸附实验(enzyme-linked immunosorbent assay,ELISA)检测79例NSCLC与80例正常人血清TRAIL的表达水平;采用免疫组化法检测14例NSCLC组织中TRAIL-R2(DR5)与TRAIL-R4(Dc R2)的表达水平。结果:1、TRAIL在NSCLC血清中的表达明显高于健康人的表达水平(P=0.0030.05),差异具有统计学意义,与NSCLC的临床分期具有显著相关性(组间比较P=0.0000.05),随着分期的增加,TRAIL的表达水平逐渐降低,与病理分化程度明显相关(P=0.0000.05),NSCLC的分化程度越高,TRAIL的表达水平越高,与性别、年龄、病理分型无明显相关性。2、14例NSCLC组织中,TRAIL-R2的表达率为13/14(93%),与临床分期、病理分化具有显著相关性,Ⅲ期的表达明显低于Ⅰ期、Ⅱ期的表达(P=0.0240.05),高分化的组织TRAIL-R2(DR5)的表达明显高于低分化的表达水平(P=0.0020.05),差异具有统计学意义;TRAIL-R4的表达率为13/14(93%),随着分期的增加,TRAIL-R4(Dc R2)的表达水平升高(P=0.0420.05),高分化组织的TRAIL-R4(Dc R2)的表达显著低于低分化组织的表达(P=0.0340.05),差异具有统计学意义,TRAIL-R2的表达与TRAIL-R4的表达呈负相关,与病理分型、年龄、性别无显著相关性。结论:1.正常人与NSCLC中均有TRAIL的表达,NSCLC患者的表达水平略低。TRA的下降可能是导致NSCLC患者处于处于免疫抑制状态或者免疫功能下降的状态的原因之一,促进了肺癌的发生发展。2.TRAIL在NSCLC的表达与临床分期、病理分化程度有关,与病理分型、年龄、性别无显著相关性。3.TRAIL-R2、TRAILR4与临床分期、病理分化程度密切相关。与病理分型、年龄、性别无显著相关性。可能由于TRAIL-R2与TRAIL-R4在分布的差异性,导致了肿瘤逃避免疫监视,在肺癌的发生发展过程中起到了很重要的作用。4.TRAIL-R2与TRAIL-R4的表达呈负相关。可能与二者的分布及作用于信号传导途径协同抑制肿瘤凋亡有关。有助于动态监测肺癌患者病情,但仍需要进一步的研究证实。5.TRAIL-R2的表达为非小细胞肺癌临床治疗提供了靶点,TRAIL-R4在TRAIL诱导非小细胞肺癌细胞凋亡发挥调节作用。
[Abstract]:Objective: To study the tumor necrosis factor related apoptosis inducing ligand (tumor necerosis factor-related apoptosis-inducing ligand, TRAIL TRAIL-R2) and its receptor (DR5) and TRAIL-R4 (Dc R2) in non-small cell lung cancer (non-small lung, cancer, NSCLC) in the analysis of the expression pattern, and non-small cell lung cancer (NSCLC, Non-small Cell Lung Cancer). Pathological type, differentiation and clinical stage, early clinical findings, early treatment and provide laboratory evidence, and discuss the TRAIL for clinical research. Methods: using enzyme-linked immunosorbent assay (enzyme-linked immunosorbent, assay, ELISA) to detect the expression of NSCLC in 79 cases and 80 cases of normal human serum TRAIL; TRAIL-R2 was detected by immunohistochemical method in 14 cases of NSCLC tissues (DR5) and TRAIL-R4 (Dc R2) expression level. Results: the expression of TRAIL in 1, NSCLC in the serum was significantly higher than that of healthy people Level (P=0.0030.05), the difference was statistically significant, and NSCLC was significantly correlated with clinical stage (P=0.0000.05 group), with the increase of stage, the expression level of TRAIL decreased gradually and significantly correlated with the degree of pathological differentiation (P=0.0000.05), the higher the degree of NSCLC, the expression level of TRAIL is higher, and gender the age, pathological type, there was no correlation between.2,14 cases of NSCLC tissues, the expression rate of TRAIL-R2 was 13/14 (93%), and clinical stage, pathological differentiation has a significant correlation, the expression of stage III was significantly lower than that in stage I, the expression of phase II (P=0.0240.05), highly differentiated tissue TRAIL-R2 (DR5) was significantly higher than that in the expression level of low differentiation (P=0.0020.05), the difference was statistically significant; the expression rate of TRAIL-R4 was 13/14 (93%), with the increase of stage TRAIL-R4 (Dc R2) increased the expression level (P=0.0420.05), high TRAIL-R4 (Dc R2 organization) The expression was significantly lower than the expression in low differentiation tissues (P=0.0340.05), the difference was statistically significant, TRAIL-R4 had negative correlation with TRAIL-R2, and the pathological type, age, no significant correlation between gender. Conclusion: the expression of TRAIL was 1. in normal and NSCLC, decrease the expression level of NSCLC in patients with lower.TRA may be the cause of NSCLC patients in one of the reasons in immunosuppressed or decreased immune function status, promote the development of.2.TRAIL in lung cancer NSCLC expression and clinical stage, pathological differentiation, and pathological type, age, gender, no significant correlation between.3.TRAIL-R2, TRAILR4 and clinical stage, closely related to pathological differentiation. With the pathological type, age and gender. There is no significant correlation between TRAIL-R2 and TRAIL-R4 may be due to differences in distribution, leads to tumor escape immune surveillance, occurred in lung cancer In the process of development has played a very important role in.4.TRAIL-R2 expression of TRAIL-R4 and the negative correlation. The distribution and effect may be related to the two in the signal transduction pathway of apoptosis. Tumor inhibition contributes to the dynamic monitoring of lung cancer patients, but still need further study to confirm the expression of.5.TRAIL-R2 provides a target for the clinical treatment of non small cell lung cancer, TRAIL-R4 in TRAIL induced non small cell lung cancer cell apoptosis play a regulatory role.

【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R734.2

【相似文献】